menu
    • menu

    Company profile for Graphite Bio

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a broad range of severe diseases. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Graphite BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    279 E. Grand Avenue Suite 430 South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://graphitebio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LENZ Announces Completion of Merger with Graphite Bio
    LENZ Announces Completion of Merger with Graphite Bio

    21 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240321281097/en

    BUSINESSWIRE
    21 Mar 2024
    Share Share
    Graphite Bio Declares Dividend In Connection with Proposed Merger with Lenz
    Graphite Bio Declares Dividend In Connection with Proposed Merger with Lenz

    08 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240308823204/en

    BUSINESSWIRE
    08 Mar 2024
    Share Share
    Graphite Bio co-founder debuts Treg cell therapy startup with $75M
    Graphite Bio co-founder debuts Treg cell therapy startup with $75M

    17 Jan 2024

    // ENDPTS

    https://endpts.com/graphite-bio-co-founder-debuts-treg-cell-therapy-startup-with-75m-aims-to-trick-immune-system-into-resetting/

    ENDPTS
    17 Jan 2024
    Share Share
    Graphite founder takes drug to Kamau Therapeutics for a second chance: #ASH23
    Graphite founder takes drug to Kamau Therapeutics for a second chance: #ASH23

    11 Dec 2023

    // Max Gelman ENDPTS

    https://endpts.com/kamau-therapeutics-presents-follow-up-data-on-nula-cel-after-side-effects-doomed-graphite-bio/

    Max Gelman ENDPTS
    11 Dec 2023
    Share Share
    Graphite Bio divests gene editing pipeline to newly-formed biotech
    Graphite Bio divests gene editing pipeline to newly-formed biotech

    08 Dec 2023

    // Ayisha Sharma ENDPTS

    https://endpts.com/graphite-bio-divests-gene-editing-pipeline-to-newly-formed-kamau-therapeutics-after-announcing-reverse-merger-with-lenz-therapeutics/

    Ayisha Sharma ENDPTS
    08 Dec 2023
    Share Share
    Graphite hands Nasdaq spot to presbyopia biotech Lenz as PhIII readouts loom
    Graphite hands Nasdaq spot to presbyopia biotech Lenz as PhIII readouts loom

    15 Nov 2023

    // ENDPTS

    https://endpts.com/graphite-bio-makes-reverse-merger-deal-with-presbyopia-biotech-lenz-therapeutics/

    ENDPTS
    15 Nov 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search